A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study

Autor: H. de Graaf, M. Polee, Anna K.L. Reyners, Willem M. Smit, A.N.M. Wymenga, Pax H.B. Willemse, Frans L. G. Erdkamp, M A T M van Vugt, Roy I. Lalisang, L. de Munck, K. Hoekman, Michael Schaapveld, Harry Hollema

Publikováno v: Annals of Oncology, 23(11), 2896-2902. Oxford University Press
Reyners, A K L, de Munck, L, Erdkamp, F L G, Smit, W M, Hoekman, K, Lalisang, R I, de Graaf, H, Wymenga, A N M, Polee, M, Hollema, H, van Vugt, M A T M, Schaapveld, M & Willemse, P H B 2012, ' A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study ', Annals of Oncology, vol. 23, no. 11, pp. 2896-2902 . https://doi.org/10.1093/annonc/mds107

In ovarian cancer, cyclooxygenase-2 (COX-2) overexpression is prognostic for poor survival. We investigated the efficacy of celecoxib (C), a selective COX-2 inhibitor, added to docetaxel (Taxotere)/carboplatin (DC) in advanced ovarian cancer.In a pha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9feaf5205ed72630763bee110dca8b9a
https://hdl.handle.net/1871/42345

Adding the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin in first line for stage IC-IV epithelial ovarian cancer: A randomized phase II study

Autor: K. Hoekman, An K.L. Reyners, Willem M. Smit, M. A. Wymenga, H. Graaf, Phb Willemse, Roy I. Lalisang, M. Polee, Frans L. G. Erdkamp, Michael Schaapveld

Publikováno v: Journal of Clinical Oncology. 27:5545-5545

5545 Background: Inhibition of COX-2 reduces the growth rate of tumors in vitro and COX-2 is over-expressed in ovarian cancer, so a COX-2 inhibitor might be beneficial. Methods: After debulking surgery patients (pts) with advanced epithelial ovarian

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1e8d3d7bb62e99ae78b9e03b2e8aafb9
https://doi.org/10.1200/jco.2009.27.15_suppl.5545

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.